Greenwich LifeSciences, Inc.

Stocks

GLSI

US3968791083

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 12:15:17 2026-06-11 pm EDT			5-day change	1st Jan Change
22.47 ^USD	+1.63%		-5.72%	+6.21%

Jun. 04	Greenwich LifeSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Jun. 01	Greenwich LifeSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Greenwich LifeSciences, Inc. Auditor Raises 'Going Concern' Doubt

Published on 05/31/2026

S&P Capital IQ

GREENWICH LIFESCIENCES, INC.

+1.63%

Greenwich LifeSciences, Inc. filed its 10-K on Jun 01, 2026 for the period ending Dec 31, 2025. In this report its auditor, Malone & Bailey, PLLC, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Latest news about Greenwich LifeSciences, Inc.

Jun. 04	Greenwich LifeSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Jun. 01	Greenwich LifeSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Jun. 01	Greenwich LifeSciences, Inc. Presents FLAMINGO-01 Phase III Trial Open Label Data At Asco Annual Meeting 2026	CI
Jun. 01	Greenwich LifeSciences Says Audit of 2025 Form 10-K Filing in Final Stages of Approval	MT
Jun. 01	Greenwich LifeSciences provides update regarding Form 10-K filing	RE
May. 31	Greenwich LifeSciences, Inc. Auditor Raises 'Going Concern' Doubt	CI
Apr. 23	Greenwich Lifesciences Announces Acceptance of Abstract At ASCO 2026	CI
Apr. 14	Greenwich Lifesciences Provides Update on Clinical Trial and Product Pipeline	CI
Apr. 07	Greenwich LifeSciences Files New Patent Claims for Breast Cancer Immunotherapy Candidate Based on Phase 3 Data	MT
Apr. 07	Greenwich LifeSciences provides update on patent claims potentially doubling GP2 market potential	RE
Apr. 07	Greenwich LifeSciences Provides Update On Patent Claims Potentially Doubling GP2 Market Potential	CI
Mar. 19	Greenwich LifeSciences Inc initiates new US clinical sites for Flamingo-01 phase III trial	RE
Mar. 19	Greenwich LifeSciences, Inc. Announces Addition of City of Hope to Flamingo-01	CI
Mar. 19	Greenwich LifeSciences Initiates Clinical Trial Sites for Potential Breast Cancer Recurrence Therapy	MT
Mar. 18	Greenwich Lifesciences provides update on upcoming AACR meeting	RE

Chart Greenwich LifeSciences, Inc.

Duration

Period

GLSI: Dynamic Chart

Company Profile

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9-amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2) /neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. It has commenced a Phase III clinical trial, Flamingo-01, an immunotherapy to prevent breast cancer recurrences. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. Its cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells while not affecting normal cells or to deliver immune system components to inhibit the spread of cancer.

Employees

Sector

Biotechnology & Medical Research

More about the company